What is Orforglipron?
Orforglipron is a once-daily pill that activates the GLP-1 receptor, the same target as semaglutide and tirzepatide. Unlike them it is not a peptide but a small-molecule drug, which is why it works as a tablet without food or water rules. The FDA approved it in April 2026 as Foundayo for weight management in adults with obesity, or overweight with a weight-related condition.
Biological role or research focus
Weight loss with a GLP-1 pill that has no food or water restrictions.
The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest.
Role reference: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Names you may encounter
Foundayo · LY3502970
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Once-daily oral small-molecule GLP-1 receptor agonist (not a peptide); approved by the FDA in April 2026 as Foundayo
- Research focus
- Weight loss with a GLP-1 pill that has no food or water restrictions
- Featured evidence
- Human randomized phase 3 trial
- Source check
- November 12, 2026
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Quick answers
- Is Orforglipron FDA approved?
- Yes. Foundayo tablets (NDA 220934, approved April 1, 2026), a once-daily oral GLP-1 receptor agonist for weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. Source ↗
- Is Orforglipron safe?
- Orforglipron (Foundayo) is an approved GLP-1 pill whose side effects match the GLP-1 class: mostly stomach and gut effects, with the same thyroid boxed warning as the injections. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Orforglipron banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Orforglipron?
- Yes. Our records list 2 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| ATTAIN-1: orforglipron versus placebo for 72 weeks in adults with obesity (2025) | Human randomized phase 3 trial | 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 3 trial · 2025
ATTAIN-1: orforglipron versus placebo for 72 weeks in adults with obesity
What did this publication test, and what did it find?
- Population / model
- 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes.
- Study design
- Multinational, double-blind, placebo-controlled phase 3 trial. Participants were randomly assigned to one of three orforglipron dose levels or placebo for 72 weeks, alongside diet and activity advice. The main outcome was the percent change in body weight.
- Main finding
- Counting everyone randomized, average weight change at 72 weeks was -7.5%, -8.4% and -11.2% across the three dose levels versus -2.1% with placebo. On the highest dose, 54.6% lost at least 10% of their weight and 18.4% lost at least 20%. Waist size, blood pressure, triglycerides and non-HDL cholesterol also improved.
- Limits & context
- The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
53 registered studies name Orforglipron as an intervention; 17 are recruiting or under way, 3 have not started recruiting yet and 33 completed. Checked November 19, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 53 listed studies.
Search additional PubMed records ↗Risks & interactions
Orforglipron (Foundayo) is an approved GLP-1 pill whose side effects match the GLP-1 class: mostly stomach and gut effects, with the same thyroid boxed warning as the injections.
Thyroid C-cell tumors occurred in rodents given GLP-1 receptor agonists; whether this applies to people is unknown. Not for people with a personal or family history of medullary thyroid cancer or MEN 2.
The April 2026 FDA label rests on the ATTAIN and ACHIEVE phase 3 trials. In ATTAIN-1, side effects led 5.3% to 10.3% to stop, versus 2.7% on placebo. In November 2026 the FDA added a NAION (sudden vision loss) warning to all GLP-1 medicines. Long-term and heart-outcome data are not yet available.
Take extra care with: Diabetes or blood-sugar medicinesCancer, now or in the pastKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Personal or family history of medullary thyroid cancer (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Known serious allergy to orforglipron or the tablet ingredients
Interactions
- Strong CYP3A4 inhibitors or inducers: can change how much orforglipron reaches the blood
- Insulin or insulin secretagogues such as sulfonylureas: higher risk of low blood sugar
- Other oral medicines, including oral birth control pills: slowed stomach emptying may change absorption
- Simvastatin: levels may change (see label)
Serious risks
- Acute pancreatitis
- Severe stomach and gut reactions
- Kidney injury from dehydration
- Gallbladder disease
- Low blood sugar when used with insulin or sulfonylureas
- Breathing in stomach contents during anesthesia or deep sedation
Common side effects
- nausea
- constipation
- diarrhea
- vomiting
- indigestion
- stomach pain
- headache
- hair loss
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Foundayo (orforglipron) prescribing information (DailyMed) ↗ · Drugs@FDA: Foundayo, NDA 220934 ↗ · Wharton et al., NEJM 2025: ATTAIN-1 trial of orforglipron ↗ · FDA Drug Safety Communication: GLP-1 receptor agonists and NAION, November 2026 ↗
Safety & what remains unknown
Stomach and gut side effects were the most common, mostly mild to moderate. Side effects led 5.3% to 10.3% of people on orforglipron to stop, versus 2.7% on placebo. The label carries the GLP-1 class boxed warning about thyroid C-cell tumors in rodents, and in November 2026 the FDA added a warning about NAION, a rare cause of sudden vision loss, to all GLP-1 medicines. The prescribing information is the reference for precautions and drug interactions.
Source: Foundayo prescribing information (DailyMed) ↗
Evidence boundaries
The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Regulatory status
- U.S. FDA approval
- Approved
Foundayo tablets (NDA 220934, approved April 1, 2026), a once-daily oral GLP-1 receptor agonist for weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and physical activity. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
FDA actions
- FDA approved Foundayo (orforglipron) 50 days after filing under its Commissioner's National Priority Voucher pilot program, the first new molecular entity approved through the program. (2026-04-01) source
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- China, November 12, 2026: the country’s medicine regulator approved orforglipron as a weight-loss pill, Reuters reported. It was approved in the US as Foundayo in April 2026. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
Orforglipron is a prescription medicine for weight management, used with a reduced-calorie diet and more physical activity. It has also been tested in type 2 diabetes, including a head-to-head trial against the semaglutide pill. It is not a research peptide, and PepsRadar does not link to sellers from this page; products sold online as research-grade orforglipron are not Foundayo. For how it compares with the injections and the Wegovy pill, see the guides linked below.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Biology & proposed mechanism
GLP-1 is a gut hormone that slows stomach emptying, lowers appetite and helps the pancreas release insulin when blood sugar rises. Orforglipron switches on the GLP-1 receptor like the injectable medicines do, but it is a compact chemical rather than a chain of amino acids, so it survives digestion well enough to be absorbed from a pill.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Questions worth asking
- Is orforglipron a peptide?
- What material, population, and route were actually studied?
- The trial was funded by Eli Lilly, lasted 72 weeks and measured weight and risk factors, not heart attacks, strokes or deaths. No trial has compared orforglipron directly with injectable semaglutide or tirzepatide for weight loss, and results from separate trials are not a direct contest.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is orforglipron a peptide?
No. It acts on the same GLP-1 receptor as peptide drugs like semaglutide, but it is a small-molecule drug. That is what lets it be taken as a daily pill without the empty-stomach and water rules of the semaglutide pill. It is included here because it is part of the GLP-1 medicine family people compare.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment · 2025 ↗
References & editorial record
Source notes checked 2026-11-12. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
